- Home
- AD vs ABVX Comparison
AD vs ABVX Comparison
Compare AD & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AD
- ABVX
- Stock Information
- Founded
- AD 1983
- ABVX 2013
- Country
- AD United States
- ABVX France
- Employees
- AD N/A
- ABVX N/A
- Industry
- AD Telecommunications Equipment
- ABVX
- Sector
- AD Telecommunications
- ABVX
- Exchange
- AD Nasdaq
- ABVX Nasdaq
- Market Cap
- AD 6.4B
- ABVX 5.3B
- IPO Year
- AD N/A
- ABVX N/A
- Fundamental
- Price
- AD $51.05
- ABVX $84.01
- Analyst Decision
- AD
- ABVX Strong Buy
- Analyst Count
- AD 0
- ABVX 8
- Target Price
- AD N/A
- ABVX $90.63
- AVG Volume (30 Days)
- AD 298.9K
- ABVX 1.2M
- Earning Date
- AD 10-31-2025
- ABVX 08-11-2025
- Dividend Yield
- AD 45.03%
- ABVX N/A
- EPS Growth
- AD N/A
- ABVX N/A
- EPS
- AD N/A
- ABVX N/A
- Revenue
- AD $3,700,000,000.00
- ABVX $7,073,400.00
- Revenue This Year
- AD $0.37
- ABVX $25.23
- Revenue Next Year
- AD N/A
- ABVX N/A
- P/E Ratio
- AD N/A
- ABVX N/A
- Revenue Growth
- AD N/A
- ABVX N/A
- 52 Week Low
- AD $50.44
- ABVX $4.77
- 52 Week High
- AD $79.17
- ABVX $92.91
- Technical
- Relative Strength Index (RSI)
- AD N/A
- ABVX 67.94
- Support Level
- AD N/A
- ABVX $82.72
- Resistance Level
- AD N/A
- ABVX $91.30
- Average True Range (ATR)
- AD 0.00
- ABVX 3.62
- MACD
- AD 0.00
- ABVX -1.13
- Stochastic Oscillator
- AD 0.00
- ABVX 47.89
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.